{
    "clinical_study": {
        "@rank": "10132", 
        "brief_summary": {
            "textblock": "To assess the safety and efficacy of subcutaneously administered sargramostim (\n      granulocyte-macrophage colony-stimulating factor; GM-CSF ) in increasing and maintaining the\n      neutrophil count in HIV-infected adults who have developed neutropenia as a result of\n      receiving the antiretroviral agent, zidovudine ( AZT ). To assess the safety and efficacy of\n      subcutaneously administered GM-CSF in increasing and maintaining the neutrophil count in\n      HIV-infected adults with pre-existing neutropenia who are at high risk of developing\n      hematologic intolerance while receiving the antiretroviral agent, AZT, for the first time.\n      To assess the potential therapeutic benefit of concomitant GM-CSF and AZT on the natural\n      history of HIV infection and associated infectious complications."
        }, 
        "brief_title": "A Phase I/II Pilot Study of Simultaneously Administered Rhu GM-CSF ( CHO Cell ) and Azidothymidine ( AZT ) in Patients With Severe HIV Infection and Leukopenia: Pharmacokinetics and Feasibility", 
        "condition": [
            "HIV Infections", 
            "Cytopenias"
        ], 
        "condition_browse": {
            "mesh_term": [
                "HIV Infections", 
                "Acquired Immunodeficiency Syndrome", 
                "Leukopenia"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria\n\n        Concurrent Treatment:\n\n        Allowed:\n\n          -  Minimal local irradiation for tumors.\n\n        Patients must have:\n\n          -  Diagnosis of AIDS or AIDS related complex (ARC).\n\n          -  Neutropenia, due either to zidovudine (AZT) or HIV infection.\n\n          -  Life expectancy = or > 6 months.\n\n        Exclusion Criteria\n\n        Co-existing Condition:\n\n        Patients with the following conditions or symptoms are excluded:\n\n          -  Significant malabsorption as defined by greater than 10 percent weight loss and one\n             or more of the following:\n\n          -  Serum carotene less than 75 IU/ml.\n\n          -  Vitamin A level less than 75 IU/ml.\n\n          -  More than 4 foul-smelling or greasy stools per day.\n\n          -  Other criteria of malabsorption.\n\n          -  Kaposi's sarcoma (KS) or other tumor which is likely to require specific antitumor\n             therapy during study, other than minimal local irradiation.\n\n          -  Active, life-threatening infection with bacterial, viral, fungal, or protozoan\n             pathogens or fever of 39 degrees C within 10 days of study entry, unless it is\n             apparent that the fever is not due to a severe underlying infection.\n\n        Concurrent Medication:\n\n        Excluded within 4 weeks of study entry:\n\n          -  Any investigational drug.\n\n          -  Immunomodulating agents.\n\n          -  Hormonal therapy.\n\n          -  Cytolytic chemotherapeutic agents.\n\n          -  Antiretroviral agent other than zidovudine (AZT).\n\n          -  Excluded within 4 months of study entry:\n\n          -  Suramin.\n\n          -  Excluded within 3 months of study entry:\n\n          -  Ribavirin.\n\n        Patients with the following are excluded:\n\n          -  Significant malabsorption.\n\n          -  Tumor likely to require specific antitumor therapy during study.\n\n          -  Other significant medical problems and conditions specified in Patient Exclusion\n             Co-Existing Conditions.\n\n          -  Uncorrected nutritional deficiencies that may contribute to neutropenia.\n\n          -  Hypersensitivity to zidovudine (AZT) or other nucleoside analogs.\n\n          -  Profound dementia or altered mental status that would prohibit the giving of informed\n             consent.\n\n        Prior Treatment:\n\n        Excluded within 1 month of study entry:\n\n          -  Transfusion.\n\n          -  Excluded within 4 weeks of study entry:\n\n          -  Radiation therapy to greater than 100 cm2 body area.\n\n        Current drug or alcohol abuse. Unprotected sexual behavior or other activities which might\n        introduce a new inoculation of HIV during the study.\n\n        Patients must be willing to refrain from unprotected sexual or other activities which\n        might introduce a new inoculum of HIV during the study."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "firstreceived_date": "November 2, 1999", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00002006", 
            "org_study_id": "067A", 
            "secondary_id": "07936"
        }, 
        "intervention": [
            {
                "intervention_name": "Zidovudine", 
                "intervention_type": "Drug"
            }, 
            {
                "intervention_name": "Sargramostim", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Zidovudine"
        }, 
        "keyword": [
            "Neutropenia", 
            "Drug Interactions", 
            "Granulocyte-Macrophage Colony-Stimulating Factor", 
            "Acquired Immunodeficiency Syndrome", 
            "Zidovudine"
        ], 
        "lastchanged_date": "June 23, 2005", 
        "location": {
            "facility": {
                "address": {
                    "city": "Bethesda", 
                    "country": "United States", 
                    "state": "Maryland", 
                    "zip": "20892"
                }, 
                "name": "Natl Cancer Institute"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "A Phase I/II Pilot Study of Simultaneously Administered Rhu GM-CSF ( CHO Cell ) and Azidothymidine ( AZT ) in Patients With Severe HIV Infection and Leukopenia: Pharmacokinetics and Feasibility", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 1", 
        "reference": {
            "PMID": "1742482", 
            "citation": "Levine JD, Allan JD, Tessitore JH, Falcone N, Galasso F, Israel RJ, Groopman JE. Recombinant human granulocyte-macrophage colony-stimulating factor ameliorates zidovudine-induced neutropenia in patients with acquired immunodeficiency syndrome (AIDS)/AIDS-related complex. Blood. 1991 Dec 15;78(12):3148-54."
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00002006"
        }, 
        "source": "NIH AIDS Clinical Trials Information Service", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Sandoz Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "study_design": "Endpoint Classification: Pharmacokinetics Study, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 1990"
    }, 
    "geocoordinates": {
        "Natl Cancer Institute": "38.985 -77.095"
    }
}